X0202 SCHEDULE 13G 0002077247 XXXXXXXX LIVE Class A Common Stock, $0.001 par value per share 09/22/2026 0001855175 Contineum Therapeutics, Inc. 21217B100 3565 General Atomics Court, Suite 200 San Diego CA 92121 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 1679443.00 0.00 1679443.00 0.00 1679443.00 N 5.1 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 1679443.00 0.00 1679443.00 0.00 1679443.00 N 5.1 PN See Item 4 for additional information. Ortav Yehudai X1 1679443.00 0.00 1679443.00 0.00 1679443.00 N 5.1 IN See Item 4 for additional information. Contineum Therapeutics, Inc. 3565 General Atomics Court, Suite 200, San Diego, CA, 92121 This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"), Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology"), and Ortav Yehudai ("Mr. Yehudai"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology, and Mr. Yehudai is the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3445 Peachtree Road NE, Suite 900, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of September 22, 2026 (the "Event Date"), each Filer may be deemed to beneficially own an aggregate of 1,679,443 shares of Class A Common Stock, $0.001 par value per share (the "Shares"), of Contineum Therapeutics, Inc. (the "Issuer"). The 1,679,443 Shares reported as beneficially owned on this Schedule 13G by each Filer consist of 1,679,443 Shares held directly by Trails Edge Biotechnology. As a result, Trails Edge Biotechnology beneficially owns 5.1% of the outstanding Shares of the Issuer as of the Event Date. Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 5.1% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on 32,958,632 Shares issued and outstanding as of July 24, 2026, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 30, 2026. 5.1 1,679,443 0.00 1,679,443 0.00 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1- Joint Filing Agreement Trails Edge Capital Partners, LP /s/ Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 10/22/2026 Trails Edge Biotechnology Master Fund, LP /s/ Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 10/22/2026 Ortav Yehudai /s/ Ortav Yehudai 10/22/2026